A Study to Compare Golcadomide and Rituximab vs Investigator's Choice in Follicular Lymphoma
Phase 3
400
about 5 years
18+
31 sites in AK, AL, AR +14
About this study
Researchers are testing whether golcadomide combined with rituximab is more effective than a treatment chosen by the doctors (investigator's choice) for people whose follicular lymphoma has returned after other treatments. The trial will last about 1829 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bendamustine
- 2.Take Cyclophosphamide
- 3.Take Doxorubicin
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bendamustine, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), prednisolone, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, oral (Oral Capsule), oral (Disintegrating Oral Tablet), oral
Primary: Progression free survival (PFS) assessed by Independent Review Adjudication committee (IRAC)
Secondary: Duration of Response (DoR), Event free survival (EFS), Minimal residual disease (MRD) negativity, ORR as assessed by investigator, Overall response rate (ORR) assessed by IRAC, Overall survival (OS), PFS as assessed by investigator, PFS on next anti-lymphoma treatment (PFS2)
Oncology